Piboserod is primarily investigated for its potential therapeutic applications in the field of cardiology. It functions as a selective serotonin 5-HT4 receptor antagonist, which makes it a candidate for treating conditions like atrial fibrillation and heart failure. By blocking these receptors, it may help regulate heart rhythm and improve cardiac function. Research has also explored its role in reducing the risk of arrhythmias, particularly in patients with underlying heart conditions. Additionally, its mechanism of action suggests potential benefits in managing gastrointestinal disorders linked to serotonin receptor activity, although this remains an area of ongoing study. Clinical trials continue to evaluate its efficacy and safety in these applications.